8-K: Nexalin Appoints Veteran Financial Leader Justin Van Fleet as CFO

Nexalin Technology, Inc. announced the appointment of Justin Van Fleet, a seasoned public accounting expert, as its new Chief Financial Officer, effective August 1, 2025.

Summary

• Justin Van Fleet was appointed Chief Financial Officer of Nexalin Technology, Inc., effective August 1, 2025.
• Mr. Van Fleet brings over 20 years of experience in public accounting, having previously served as a partner in the assurance practice of Marcum LLP (formerly Friedman LLP).
• His expertise includes advising public and private clients across technology, life sciences, manufacturing, and distribution sectors.
• He is recognized for his integrity, technical expertise, and strategic leadership, particularly in guiding companies through complex financial transactions like IPOs and mergers.
• As CFO, Mr. Van Fleet will oversee Nexalin's financial strategy, planning, and reporting functions.
• Nexalin's Generation 2 and Generation 3 neurostimulation devices are currently under FDA review.
• The Nexalin Gen-2 15 milliamp neurostimulation device has already been approved in China, Brazil, and Oman.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced CFO with a strong background in public accounting, regulatory compliance, and strategic financial management is a significant positive development, indicating the company's focus on scaling operations and preparing for commercialization of its innovative neurostimulation devices.

Positives

• The appointment of Justin Van Fleet, a highly experienced CFO with over two decades in public accounting and assurance services, strengthens the executive leadership team.
• Mr. Van Fleet's expertise in regulatory compliance, strategic financial management, IPOs, and mergers will be invaluable as the company scales operations.
• His track record includes developing robust financial systems, mentoring high-performing teams, and ensuring compliance with professional and regulatory standards.
• The CEO, Mark White, expressed enthusiasm for Mr. Van Fleet's deep expertise, which is expected to be crucial for advancing the neurostimulation platform.
• The company's innovative non-invasive neurostimulation systems (Gen 2 & Gen 3) are progressing through regulatory review, indicating potential future market entry.
• The Gen-2 device has already secured international approvals in China, Brazil, and Oman, demonstrating global market potential.

Risks

• Forward-looking statements contained in the press release involve risks and uncertainties that could cause actual events or results to differ materially from those indicated.
• Risks are detailed in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024, and other filings with the Securities and Exchange Commission.

Future Outlook

The company is at a pivotal moment with a highly differentiated technology platform that holds significant promise for treating serious mental health conditions. The new CFO will oversee financial strategy as the company advances its innovative neurostimulation systems through regulatory review and into commercial readiness, aiming to drive the next phase of growth and innovation.

Management Comments

• Mark White, CEO of Nexalin Technology: "We are thrilled to welcome Justin to the Nexalin executive leadership team. His deep expertise in public accounting, regulatory compliance, and strategic financial management will be invaluable as we scale our operations and continue advancing our groundbreaking neurostimulation platform."
• Justin Van Fleet, CFO of Nexalin Technology: "Nexalin is at a pivotal moment, with a highly differentiated technology platform that holds enormous promise for treating serious mental health conditions. I’m honored to join the team and contribute to the financial discipline and scalability needed to support Nexalin’s ambitious goals. This is an exciting time for the Company, and I look forward to helping drive its next phase of growth and innovation."

Industry Context

Nexalin Technology operates in the rapidly evolving neurostimulation and bioelectronic medical technology sector, focusing on non-invasive solutions for mental health disorders. Its Deep Intracranial Frequency Stimulation (DIFS) technology positions it as a player in addressing the global mental health epidemic, offering an alternative to traditional drug-based or invasive treatments for conditions like anxiety and depression.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Likely positive impact due to the addition of a seasoned financial leader, potentially leading to improved financial management, transparency, and strategic growth, which could enhance shareholder value.
• Employees: Potential for improved financial systems, stronger internal controls, and mentorship from a highly experienced CFO.
• Customers/Patients: Indirect positive impact as the CFO's role supports the advancement and commercialization of devices designed to treat mental health conditions, potentially bringing new treatment options to market faster.

Next Steps

• Scale company operations.
• Continue advancing the groundbreaking neurostimulation platform.
• Advance innovative non-invasive neurostimulation systems through regulatory review (FDA).
• Achieve commercial readiness for Generation 2 and Generation 3 devices.
• Drive the next phase of growth and innovation for the company.

Key Dates

Recommendation

The appointment of a highly experienced Chief Financial Officer is a positive development for Nexalin Technology, signaling a focus on financial discipline, scalability, and strategic growth as the company advances its neurostimulation devices. This strengthens the management team and is a favorable indicator for future operational efficiency and regulatory compliance. However, as this filing primarily concerns a personnel change rather than financial results or new strategic initiatives with immediate quantifiable impact, a 'hold' recommendation is appropriate. Investors should monitor future filings for financial performance and regulatory milestones.

Keywords

Nexalin Technology, NXL, NXLIW, CFO, Chief Financial Officer, Justin Van Fleet, neurostimulation, mental health, Deep Intracranial Frequency Stimulation, DIFS, public accounting, financial management, FDA review, medical technology, life sciences